Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine

Authors :: Block, Stan L.
Brown, Darron R.
Chatterjee, Archana
Gold, Michael A.
Sings, Heather L.
Meibohm, Anne
Dana, Adrian
Haupt, Richard M.
Barr, Eliav
Tamms, Gretchen M.
Zhou, Haiping
Reisinger, Keith S.
Source :: The Pediatric Infectious Disease Journal; February 2010, Vol. 29 Issue: 2 p95-101, 7p
Publication Year :: 2010
Abstract: We describe the safety of the human papillomavirus (HPV)-6/11/16/18 vaccine using updated clinical trial data (median follow-up time of 3.6 years) and summarize up to 3 years of post-licensure surveillance.

Full Text Access

Tools